Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Xiaolu Long"'
Autor:
Xiaolu Long, Ning An, Chunhui Li, Hui Zhu, Haojie Li, Qiuxia Yu, Yimei Que, Menglei Xu, Zhe Li, Wei Chen, Shuai Wang, Di Wang, Chunrui Li
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
The outcome of AL amyloidosis remains poor, particularly in patients with advanced organ involvement which takes long time to recovery. We conducted an observational study of two patients with AL amyloidosis treated with SDd regimen. Both patients su
Externí odkaz:
https://doaj.org/article/a3e188e780cc45aa8108badce038c569
Autor:
Di Wang, Haiying Fu, Yimei Que, Haitao Ruan, Menglei Xu, Xiaolu Long, Qiuxia Yu, Chunhui Li, Zhe Li, Songbai Cai, Wei Chen, Cong Sun, Guang Hu, Shuai Wang, Donggou He, Jianming Mei, Wen Wang, Chunrui Li
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Extramedullary disease usually implies a dismal outcome in relapsed/refractory multiple myeloma patients, and requires novel treatment approaches. We designed a trial using Selinexor, a nuclear export protein 1 inhibitor, together
Externí odkaz:
https://doaj.org/article/f3a34539f48349448a5f00e1e8c45a6c
Autor:
Yi Xiao, Man Zhang, Jin Jin, Liting Chen, Xiaolu Long, Caixia Chen, Jiao Meng, Wanying Liu, Aichun Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 11 (2023)
Background Chimeric antigen receptor (CAR) T cell therapy is an advanced and effective immunotherapy for relapsed or refractory B-cell malignancies. High expansion of CAR T cells in vivo and durable antitumor activity indicate a persistent therapeuti
Externí odkaz:
https://doaj.org/article/5c418737b0cd4b148d42b855b41891cb
Autor:
Wei Mu, Xiaolu Long, Haodong Cai, Caixia Chen, Guang Hu, Yaoyao Lou, Shugang Xing, Di Wang, Jue Wang, Min Xiao, Kun Wang, Zhongyi Sun, Chunrui Li, Jianfeng Zhou, Liting Chen
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Different from canonical drugs, CAR T-cells are “living drugs”, which derived from patient’s own blood. Studies of the pharmacokinetics of CAR T-cells could improve our understanding of their efficacy, safety, optimal dosage, and other characte
Externí odkaz:
https://doaj.org/article/74c0e198ea20496a9dc83f5be0223190
Publikováno v:
Pakistan Journal of Medical Sciences; Jan/Feb2024, Vol. 40 Issue 1, p120-127, 8p
Autor:
Liting Chen, Gaoxiang Wang, Jiaqi Tan, Yang Cao, Xiaolu Long, Hui Luo, Qing Tang, Tiebin Jiang, Wei Wang, Jianfeng Zhou
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 5, Iss 1, Pp 1-3 (2020)
Externí odkaz:
https://doaj.org/article/fbce5d466ede4a20b594232621f340a9
Autor:
Jia Wei, Zekai Mao, Na Wang, Lifang Huang, Yang Cao, Weimin Sun, Xiaolu Long, Jiaqi Tan, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Yicheng Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Publikováno v:
Clinical and Translational Medicine, Vol 10, Iss 5, Pp n/a-n/a (2020)
Externí odkaz:
https://doaj.org/article/1f1dfb5ea8d147449cceacd49273f789
Autor:
Tongjuan Li, Lei Zhao, Yuanyuan Zhang, Yi Xiao, Di Wang, Liang Huang, Liya Ma, Liting Chen, Songya Liu, Xiaolu Long, Fankai Meng, Xiaojian Zhu, Jia Wei, Bin Xu, Jianfeng Zhou, Xiaoxi Zhou
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Advanced central nervous system (CNS) lymphoma is an exclusion criterion for most chimeric antigen receptor (CAR) T-cell studies due to the associated levels of neurotoxicity. In this study, we described five patients with chemorefractory B-cell CNS
Externí odkaz:
https://doaj.org/article/b6f9c7191cdf46deb98798310a5a9e54
Autor:
Yi Xiao, Ying Wang, Jianfeng Zhou, Yang Cao, Jin Wang, Li Zhu, Di Wang, Na Wang, Bin Xu, Liting Chen, Xiaolu Long, Jia Gu, Yaoyao Lou, Chunrui Li, Gaoxiang Wang, Haiyun An, Min Xiao
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal out
Externí odkaz:
https://doaj.org/article/39f51c9c519f4f079bb85e3e5e488626
Publikováno v:
Diagnostics, Vol 11, Iss 11, p 2055 (2021)
Growing evidence now suggests that circulating tumour DNA (ctDNA) has great potential as a non-invasive biomarker for disease monitoring, since ctDNA carries tumour-specific modifications. In particular, monitoring ctDNA has important implications fo
Externí odkaz:
https://doaj.org/article/8018f6fc785544dda79cd281b01f0057